Cybin Corp. has become a leader in the research and development of psychedelic and nutraceutical-based products with a focus on psilocybin-based treatments.
Whitefish, Montana–(Newsfile Corp. – August 20, 2020) – CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media and the PsyIndex.com, the leading media network dedicated to the global legal cannabis, CBD and psychedelics industries, today announced the addition of Cybin Corp. to its growing psychedelics client roster.
CFN Media will leverage its proprietary digital content platform and extensive distribution, including its PsyIndex.com, to attract qualified retail, accredited and professional investors to Cybin Corp.
“Cybin has become a leader in the research and development of psychedelic delivery mechanisms, synthetic compounds, extraction methods and new drug formulations,” said CFN President Frank Lane. “We are excited to be working with the company as it transitions from a privately held to a publicly traded entity.”
Cybin is focused on furthering the research and development of psilocybin through its wholly-owned subsidiary, Serenity Life Sciences Inc. The company’s experienced management team has run multiple clinical trials and successfully brought many new drugs to market in the past.
About Cybin Corp.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/62140
Powered by WPeMatico
